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Pathological high-frequency oscillations are a novel marker used to improve the delinea-
tion of epileptogenic tissue and, hence, the outcome of epilepsy surgery. Their practical 
clinical utilization is curtailed by the inability to discriminate them from physiological 
oscillations due to frequency overlap. Although it is well documented that pathological 
HFOs are suppressed by antiepileptic drugs (AEDs), the effect of AEDs on normal HFOs 
is not well known. In this experimental study, we have explored whether physiological 
HFOs (sharp-wave ripples) of hippocampal origin respond to AED treatment. The results 
show that application of a single dose of levetiracetam or lacosamide does not reduce 
the rate of sharp-wave ripples. In addition, it seems that these new generation drugs do 
not negatively affect the cellular and network mechanisms involved in sharp-wave ripple 
generation, which may provide a plausible explanation for the absence of significant 
negative effects on cognitive functions of these drugs, particularly on memory.
Keywords: high-frequency oscillations, sharp-wave ripples, levetiracetam, lacosamide, antiepileptic drugs, 
hippocampus, ripples, in vivo
highlighTs
• Pathological high-frequency oscillations (pHFOs) represent electrographic biomarker of epilep-
togenic tissue.
• Current approaches are not able to distinguish pathological HFOs from physiological ones in 
intracranial recordings.
• Antiepileptic drugs decrease the rate of pHFOs.
• Levetiracetam or lacosamide do not decrease the rate of sharp-wave ripples—a representative of 
physiological HFOs.
• Pharmacological testing could be used to discriminate pathological and physiological HFOs.
inTrODUcTiOn
Pathological high-frequency oscillations (pHFOs) represent a new electrographic marker of epi-
leptogenic tissue. Early after their discovery, pHFO analysis was introduced into the presurgical 
evaluation to better delineate the resection margin and to improve the outcome of surgery. pHFOs 
are classified according to their frequency into two main groups—ripples (80–250 Hz) and fast rip-
ples (250–600 Hz) (1, 2). Although fast ripples are considered more specific for epileptogenic tissue 
than ripples, both types of pHFO can localize the epileptogenic zone or seizure onset areas in humans 
FigUre 1 | The algorithm of sharp-wave ripple (SWR) detection. (a) An 
example of the wideband signal containing an SWR event. (B) High-pass 
filtered (>100 Hz) signal reveals the ripple oscillation. (c) Root mean square 
(RMS) signal computed from the high-pass filtered signal. The line indicates 
the detection threshold. The shaded area marks the putative detection.  
(D) The autocorrelation function of the shaded segment of the high-pass 
filtered signal with detected peaks, which fulfills the criteria for SWR 
detection. (e) An example of a Nissl-stained brain slice with electrode tip 
located in stratum pyramidale of the CA1 hippocampal subregion.
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who undergo exploration with invasive electrodes (1, 2). Several 
studies have demonstrated the beneficial effect of complete resec-
tion of the pHFO generating areas on surgical outcome (3–5). 
The practical utilization of pHFOs in presurgical evaluation is 
substantially hindered by the inability to differentiate them from 
physiological high-frequency oscillations, such as hippocampal 
sharp-wave ripples (SWRs) as they display substantial frequency 
overlap (2, 6, 7). Currently, we do not have any effective tools, 
which can reliably discriminate between them. Identification of 
an approach to reliably discriminate between normal and patho-
logical HFOs is a complex, but essential, issue to address if the 
properties of pHFOs are to be fully utilized in clinical practice.
One of the features of pHFOs is their responsiveness to 
antiepileptic drugs (AEDs). In the chronic pilocarpine model 
of temporal lobe epilepsy, pHFOs and seizure rate decrease 
after treatment with levetiracetam (8) or lacosamide (9). In 
humans, withdrawal of AEDs is associated with increased rate 
of pHFOs (10). A pharmacological test using AEDs could be a 
plausible strategy to discriminate physiological oscillations from 
pathological ones, providing rate of physiological HFOs is not 
decreased by AEDs.
In this proof-of-principle study, we explored the impact of a 
single dose of lacosamide or levetiracetam on the rate of SWRs—a 
hippocampal representative of physiological HFOs (11). SWRs 
play a crucial role in the process of coordinated memory reactiva-
tion and formation of long-term memory (12). We have tested 
the hypothesis that the application of a single therapeutic dose of 
levetiracetam or lacosamide does not affect SWR rate.
MaTerials anD MeThODs
electrode implantation and eeg 
recording
All experiments were performed under the Animal Care and 
Animal Protection Law of the Czech Republic fully compatible 
with the guidelines of the European Union directive 2010/63/EU. 
The protocol was approved by the Ethics Committee of The Czech 
Academy of Sciences (Project License No. 71/2016). Animals were 
housed in groups under standard conditions in a room with con-
trolled temperature (22 ± 1°C) and 12/12 h light/dark cycle. Eleven 
adult male Wistar rats weighing between 350 and 430 g were used in 
this study. The surgical preparation was performed under isoflurane 
anesthesia. The animals were implanted with bipolar twisted silver 
electrodes (120 µm in diameter, AM Systems, Inc., USA) bilaterally 
in the stratum pyramidale (AP: −4.1, L: 2.2, D: 2.5) and stratum 
radiatum (AP: −4.6, L: 2.6, D: 2.6) of the dorsal CA1 according to 
the stereotaxic atlas (13). The two contacts of each electrode were 
0.5 mm apart. Two ground/reference jeweler’s screws were placed 
over the cerebellum. Following a 5-day recovery period, animals 
were individually video-EEG monitored for 4 weeks continuously. 
Spontaneous electrographic activity was amplified, band-pass 
filtered (0.1 Hz–1.6 kHz), and digitized at 5 kHz using a RHD2132 
32-channel amplifier chip (Intan Technologies, USA). After the 
end of the experiment, animals were humanely euthanized by an 
overdose of urethane, brains extracted, and processed to verify the 
positions of electrodes (Figure 1E).
aeD Treatment
Each animal received sequential intraperitoneal injections of 
levetiracetam (Keppra®, UCB, S.A., Brussels, Belgium), saline 
(control solution) of equal volume, lacosamide (Vimpat®, 
UCB, S.A., Brussels, Belgium), and saline of equal volume. 
Additionally, three of the animals received diazepam (Apaurin®, 
Krka, d. d., Novo Mesto, Slovenia) and saline of equal volume. 
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Diazepam acted as a positive control since it was shown to 
decrease the SWR rate in  vivo (14). The interval after each 
injection, whether it was an AED or saline, was 3 days to allow 
maximal elimination of the drug from the body based on the 
known pharmacokinetics (14–16). The doses for levetiracetam 
and lacosamide were 80 and 30  mg/kg, respectively. At com-
parable doses, these drugs were shown to effectively suppress 
pHFOs (8, 9). The dose of diazepam was 1 mg/kg which was 
shown to reduce or even suppress the SWR rate (14, 17). The 
sequence of injections was randomized between animals. In a 
given rat, every injection was administered at the same time of 
the day (10:30 a.m. or 2:00 p.m.).
eeg analysis
EEGs were analyzed using custom made scripts in Matlab 2015a 
computing environment (Mathworks Inc., Natick, MA, USA). 
Two animals were removed from the analysis due to extremely 
noisy EEG signals. In one animal, the experiment was terminated 
prematurely due to the loss of the head cap prior to lacosamide 
injection. Therefore, the total number of animals used in the 
evaluation of the three drugs was nine for levetiracetam, eight 
for lacosamide, and three for diazepam. In each animal, SWRs 
were analyzed only in the  channel in which SWRs displayed the 
highest amplitude. Correct positions of these electrodes in the 
hippocampal CA1 were verified histologically. We analyzed two 
epochs each lasting 2 h. The first epoch was from 0.5 to 2.5 h after 
the injection and the second one was from 4.5 to 6.5 h after the 
injection. To determine the SWR rate during the same brain state, 
we extracted episodes of slow-wave sleep only, from each epoch, 
based on the presence of slow waves in the EEG and verified 
behaviorally in video recordings.
sWr Detection
Sharp-wave ripples were detected using the modified root mean 
square (RMS)-based approach (18). The signal was band-pass 
filtered (passband 100–200 Hz) using a FIR filter with a 40-Hz 
wide transition band and stopband attenuation at 80  dB. RMS 
value was calculated in 4  ms sliding windows. Only segments 
of at least 18 ms in duration with an RMS value >1.5 SD above 
the RMS mean were selected as putative SWRs. Events closer 
than 10 ms were treated as a single event. The next step of the 
detection procedure included estimation of the autocorrelation 
function in high-pass filtered segments (>100 Hz, otherwise the 
same parameters). Detections with at least seven peaks in the 
autocorrelation function with a lag corresponding to the SWR 
frequency band (100–200 Hz) and with the second peak of at least 
25% of magnitude were selected. The main steps of the detection 
procedure are visualized in Figures 1A–D.
To evaluate the detector’s performance, 24 randomly selected 
epochs of slow-wave sleep were labeled by an expert. Automatic 
detections were compared to the expert’s labels. A true posi-
tive (TP) detection was defined as the one overlapping with an 
expert’s label by at least 50% of the detection’s duration. A false 
positive (FP) detection was a detection not fulfilling the criteria 
for TP detection. The number of false negatives (FN) was defined 
as the number of expert’s labels, which had no overlap with any 
of the TP detections. Finally, sensitivity and positive predictive 
value (PPV) of the detector was calculated using the following 
equations:
 
sensitivity TP
TP FN
=
+  
 
PPV TP
TP FP
=
+
.
 
Sensitivity and PPV of the detector was 57 and 80%, respec-
tively. Detector’s settings were optimized to achieve mainly high 
PPV to detect only true SWRs, omit ambiguous SWRs, and to 
minimize the risk of FP detections.
statistical evaluation
In this study, the primary hypothesis tested was that injections 
of selected AEDs do not affect SWR rates. This is in contrast to 
the vast majority of drug studies, which examine and test for the 
presence of an effect of the drug on specific phenomena, includ-
ing HFOs. Thus, we had to implement an appropriate statistical 
method that tests equality and not an effect. In this study, we 
adopted the method recommended by Piaggio et al. (19). For each 
rat, each injection and each time after the injection we calculated 
average SWR rate during the slow-wave sleep epochs. Then, for 
each rat, each drug and each time after the injection, we calcu-
lated the ratio of SWR rate after AED injection to SWR rate after 
the corresponding saline injection. Since the data did not display 
normal distribution, we used a non-parametric approach. For 
each drug and each time after the injection, median of the ratios 
and its non-parametric confidence interval was calculated. The 
non-parametric confidence interval for the median is obtained 
as the k-th lowest and the k-th highest value from the sample. k 
is determined so that the true population median lies within that 
interval with confidence equal or higher than required. In our 
study, we required at least 90% confidence. For sample sizes nine 
and eight we took k = 2 which gives confidences of 96 and 93%, 
respectively. For the three diazepam animals, we took the first 
and the last value as the confidence interval (widest possible), 
which gives up to 75% confidence (20). We obtained confidence 
intervals for all three drugs and two time windows after the injec-
tions. These six confidence intervals were compared to equality 
margins, which were set to 0.75 and 1.25. If the confidence inter-
val did not cross the equality margins, the AED was considered 
to have no effect on SWR rate.
Following equality testing, we performed statistical analysis to 
evaluate the possible presence of a statistically significant effect 
of AEDs on the SWR rate. In this step, we used the Wilcoxon 
signed-rank test on each set of the ratios. Before applying the test, 
the ratios were transformed by subtracting 1 so that a decrease in 
the SWR rate resulted in a negative number and vice versa. In the 
case of a non-significant result, post hoc power of the Wilcoxon 
signed-rank test was determined using SD of the data and loca-
tion shift equal to the equality margin, i.e., 0.25 (21, 22).
resUlTs
In total 43,011 SWRs were detected with 4,779 ± 3,125 events 
per animal. The average SWR rate was 16.0 events/min, which 
FigUre 4 | Medians of ratios of sharp-wave ripple (SWR) rates after drug 
injection to rates after corresponding saline injection. Error bars represent 
non-parametric confidence intervals of the medians. Dashed line is at value 1 
which constitutes no effect. Dotted lines at values 0.75 and 1.25 represent 
equality margins. LEV confidence intervals are at 96% confidence and do not 
cross the equality margins. LCM significantly increases SWR rate 0.5 h after 
administration, but 4.5 h after administration the effect dissipates. Confidence 
intervals are 93%. DIA markedly reduces SWR rate 0.5 h after administration 
and 4.5 h after administration the effect slowly dissipates. Confidence 
intervals are 75%. LEV, levetiracetam; LCM, lacosamide; DIA, diazepam.
FigUre 3 | Ratios of sharp-wave ripple (SWR) rates after drug treatment to 
rates after saline treatment for individual rats. Dashed line is at value 1 which 
constitutes no effect. LEV, levetiracetam; LCM, lacosamide; DIA, diazepam; 
CtrlXXX, injection of an equivalent volume of saline; 0.5, half an hour after 
injection; 4.5, four and half hours after injection.
FigUre 2 | Sharp-wave ripple (SWR) rates after various treatments. Lines 
connect data points from individual animals. LEV, levetiracetam; LCM, 
lacosamide; DIA, diazepam; CtrlXXX, injection of equivalent volume of saline; 
0.5, half an hour after injection, 4.5, four and half hours after injection.
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is congruent with studies focused on SWR in vivo (11, 23–25). 
SWR rates of all animals, after each injection, in both analyzed 
time windows, are shown in Figure 2. The data revealed the pres-
ence of individual variability in the SWR rate and response to the 
tested drugs. The crucial parameter for examination of the effect 
of an AED is the ratio between the SWR rate after AED injec-
tion and the SWR rate after control saline injection (Figure 3). 
The median ratio of the SWR rate between levetiracetam and 
the control was 0.91 and 0.98 for 30  min and 4.5  h after the 
injection, respectively (n =  9 animals). For levetiracetam, the 
ratios’ confidence intervals did not cross the equality margins 
30 min and 4.5 h after injection (Figure 4). Therefore, SWR rates 
after levetiracetam and saline treatment can be considered equal 
within the equality margins. The Wilcoxon signed-rank test for 
ratios was non-significant for 30 min (p = 0.30) and 4.5 h after the 
injection (p = 0.57), with a post hoc power of 88%. For lacosamide, 
the median ratio of the SWR rate was 1.14 and 1.22 for each time 
epoch (n = 8 animals). The confidence intervals of the SWR rate 
ratios crossed the equality margins in both time windows. The 
Wilcoxon signed-rank test demonstrated a significant increase in 
SWR rate ratio 30 min after injection of lacosamide (p = 0.039). 
After 4.5 h the effect of lacosamide was non-significant (Wilcoxon 
signed-rank test; p =  0.11; power =  85%). Diazepam, which 
was used as a positive control, reduced the SWR rate compared 
to the equivalent volume of saline in all rats by >50% with a 
median ratio of 0.46 and 0.70 for each time window (Figure 4). 
However, statistical significance could not be reached due to the 
small number of rats (n = 3 animals; Wilcoxon signed-rank test; 
p = 0.25; power = 46%).
DiscUssiOn
We have shown that a single dose of levetiracetam and lacosa-
mide does not reduce the rate of SWRs—a representative of 
physiological HFOs. The ability to reliably differentiate between 
pathological and physiological HFOs represents a crucial step 
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toward the clinical utilization of pHFOs as biomarkers of the epi-
leptogenic zone (2, 7). Epileptic pHFOs display a spectral overlap 
with physiological HFOs such as SWRs or fast gamma activity. 
Fast ripples are considered to be exclusively of epileptic origin, 
but physiological activity with a frequency around ~600 Hz has 
been described in the neocortex. Matsumoto and colleagues 
described features, which discriminated task-related physi-
ological HFOs from pathological ones (26). Pathological HFOs 
were characterized by a higher spectral mean, longer duration, 
and lower mean frequency. Other studies tried to discriminate 
HFOs according to their spatial distribution, relationship with 
sleep phases (27), background activity (28), phase relationship 
with slow waves (29), or using cognitive tasks (30). However, 
the practical implementation of these criteria is challenging. 
Experimental treatment with levetiracetam or lacosamide 
has been shown to reduce the both ripples and fast ripples in 
the pilocarpine model of temporal lobe epilepsy, even though 
the effects were region specific (8, 9). In this in vivo study, we 
demonstrate that levetiracetam does not decrease the rate of hip-
pocampal SWRs. The confidence intervals were set to tolerate 
a 25% change in SWR rate after the treatment. Studies which 
explored the effect of levetiracetam and lacosamide on pHFOs 
showed that these drugs reduced the pathological ripple rate in 
hippocampal structures by an average of 57% for levetiracetam 
and by 43% for lacosamide (8, 9). Although we studied the 
effect of these AEDs only on specific subtype of physiological 
HFOs, these experimental results suggest that the procedure of 
pharmacological testing can be a plausible approach to facilitate 
discrimination between physiological and pathological HFOs. 
Both drugs are used very frequently and their withdrawal and 
subsequent introduction is a very common procedure in patients 
undergoing invasive explorations. As an alternative, the intro-
duction of AEDs could be replaced by an intravenous application 
of levetiracetam at the end of monitoring. HFOs that are not 
altered by AEDs can be considered to be physiological HFOs.
The absence of a major effect of the AEDs on the rate of SWRs 
and suppression of pHFOs can be explained by the currently 
known mechanisms of action of the drugs and cellular mecha-
nisms of HFOs (31, 32). SWRs are oscillations that reflect the 
activation of large neuronal ensembles in the hippocampal CA1 
region, particularly during sleep. On the cellular level, the oscil-
lation depends on the precise interaction between pyramidal cells 
and inhibitory interneurons. The fast inhibitory postsynaptic 
potentials on the membrane of principal neurons play a key role 
in the coordination of principal cell firing (11). Pyramidal cells 
fire heterogeneously during the SWR; some cells can fire during 
every successive event, while other cells can fire only occasionally 
(17, 33). The sequence of neuronal activity during SWRs replays 
the sequence of neuronal activation during behavioral tasks, and 
it is considered to represent a mechanism of memory reactivation 
and long-term memory formation (12, 34). The cellular dynam-
ics of pHFOs in both ripple and fast ripple bands differs and is 
more uniform (31, 32). During each pHFO, a large population 
of cells generates a burst of high-frequency action potentials 
superimposed on a large depolarizing envelope (35–37). While 
high-frequency spiking depends mainly on fast sodium channel 
kinetics, the depolarizing envelope is associated with an increase 
in intracellular calcium via the opening of voltage-gated calcium 
channels or activation of non-NMDA and NMDA receptors. 
Lacosamide modifies voltage-gated sodium channel kinetics 
required for fast action potential firing, and it affects only neurons 
which are active or depolarized for prolonged periods of time 
and thus spares physiological functions (38). Therefore, patho-
logical pHFOs are more susceptible to its effects than SWRs. The 
levetiracetam binds to SV2A, which is involved in trafficking 
and fusion of synaptic vesicles (39). It seems that levetiracetam 
reduces the vesicle release that is important for synaptic 
 neurotransmission (40). It also partially blocks N-type calcium 
channels (41). However, the exact mechanisms of its actions are 
not well known, but we can assume that levetiracetam is capable 
of interfering with cellular processes involved in intense neuronal 
firing and pHFOs.
The absence of the effect of levetiracetam and lacosamide 
on the mechanisms of SWRs, in general, can also be deduced 
indirectly from the lack of their negative effect on cognitive func-
tions including memory. It is well established that any drug or 
procedure, which has the capacity to interfere with the cellular 
mechanisms underlying the genesis of SWRs, also has the capac-
ity to induce a memory deficit (42, 43). Levetiracetam is currently 
the drug of first choice, and lacosamide has also shown its thera-
peutic benefits as add-on therapy early after its introduction into 
epilepsy therapy. Both drugs are well tolerated by patients and 
demonstrate low adverse effects and an absence of a significant 
impact on cognition and memory (44–47). From electrophysi-
ological perspective, these observations are supported by our 
experimental study, which demonstrates the absence of any sup-
pressive effect of these drugs on the SWR generation. Moreover, 
lacosamide was shown to increase the speed of complex visual 
information processing (48), which may be in agreement with the 
transiently increased SWR rate observed in this study.
A possible limitation of this study is the single-dose scheme 
of drug administration. We might have missed the time period 
of SWR suppression by the drug. However, based on the known 
pharmacokinetics and mechanism of action of these drugs this 
seems unlikely (15, 16, 38, 49). Another possibility is that the drug 
was cleared from the body before its concentration in the brain 
could have reached sufficient intrathecal levels to influence the 
SWR rate. However, we used the same dose that was administered 
daily in studies exploring the effect of lacosamide and leveti-
racetam on pHFOs (8, 9) and pharmacokinetic studies showed 
that these drugs reach maximal brain concentration within 2 h 
after application (15, 16). Another weakness of the study is the 
single-dose application. We cannot exclude that prolonged or 
chronic application of these drugs may induce long-term changes, 
which would affect the properties of SWRs.
In conclusion, we have shown that levetiracetam does not 
change the rate of SWRs and lacosamide transiently increases 
it. Hence, these drugs can be considered for pharmacological 
testing to distinguish physiological versus pHFOs. Levetiracetam 
or lacosamide could be introduced toward the end of invasive 
exploration, and the response of HFOs to the drug introduction 
could be used to determine whether the HFOs are pathological 
or physiological. Moreover, our results are congruent with studies 
showing no negative effect of these drugs on cognition.
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